Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched hla haplotype

New England Journal of Medicine

Volumn 339, Issue 17, 1998, Pages 1186-1193

  Aversa, Franco ^a   Tabilio, Antonio ^a   Velardi, Andrea ^a   Cunningham, Isabel ^a   Terenzi, Adelmo ^a   Falzetti, Franca ^a   Ruggeri, Loredana ^a   Barbabietola, Giuliana ^a   Aristei, Cynthia ^a   Latini, Paolo ^a   Reisner, Yair ^b   Martelli, Massimo F ^a   Felicini, Rita ^a   Falcinelli, Flavio ^a   Carotti, Alessandra ^a   Perruccio, Katia ^a   Ballanti, Stelvio ^a   Santucci, Antonella ^a   Gambelunghe, Cesare ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c Azienda Ospedaliera   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; FLUDARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; SOYBEAN AGGLUTININ; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LYMPHOCYTE DEPLETION; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE DEPLETION; MIDDLE AGED; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CONDITIONING;

EID: 0032558759     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199810223391702     Document Type: Article

References (53)

1. Thomas ED. Marrow transplantation for malignant diseases. J Clin Oncol 1983;1:517-31.
2. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593-602.
3. Champlin R. Bone marrow transplantation for leukemia utilizing HLA-matched unrelated donors. Bone Marrow Transplant 1993;11:Suppl 1:74-7.
4. Anasetti C, Etzioni R, Petersdorf EW, Martin PJ, Hansen JA. Marrow transplantation from unrelated volunteer donors. Annu Rev Med 1995;46: 169-79.
5. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995;60:778-83.
6. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320:197-204.
7. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313: 765-71.
8. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983;61:341-8.
9. Reisner Y, Lapidot T, Singer TS, et al. The host barrier in animal models of T-cell depleted allogeneic bone marrow transplantation. In: T cell depletion in allogeneic bone marrow transplantation. Vol. 13 of Serona symposia review. Rome: Serona Symposia, 1988:37-47.
10. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 1987;43:842-7.
11. Soiffer RJ, Mauch P, Tarbell NJ, et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 1991;7:23-33.
12. Gale RP, Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet 1986;1:1468-70.
13. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990;6:283-9.
14. Reisner Y, Ben-Bassat I, Douer D, Kaploon A, Schwartz E, Ramot B. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc Natl Acad Sci USA 1986;83:4012-5.
15. Lapidot T, Lubin I, Terenzi A, Faktorowich Y, Erlich PR, Reisner Y. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc Natl Acad Sci U S A 1990;87:4595-9.
16. Lubin I, Segal H, Erlich P, et al. Conversion of normal rats into SCID-like animals by means of bone marrow transplantation from SCID donors allows engraftment of human peripheral blood mononuclear cells. Transplantation 1995;60:740-7.
17. Bachar-Lustig E, Rachamim N, Li H-W, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268-73.
18. Cobbold SP, Martin G, Qin S, Waldmann H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 1986; 323:164-6.
19. Terenzi A, Lubin I, Lapidot T, et al. Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. Transplantation 1990;50:717-20.
20. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-55.
21. Terenzi A, Aristei C, Chionne F, Aversa F, Martelli MF, Latini P. Preliminary results in fludarabin as an immunosuppressor in bone marrow transplantation conditioning. Bone Marrow Transplant 1996;17:Suppl 1:S11. abstract.
22. Reisner Y, Friedrich W, Fabian I. A shorter procedure for preparation E-rosette-depleted bone marrow for transplantation. Transplantation 1986; 42:312-5.
23. Berenson RJ, Bensinger WI, Hill R, et al. Stem cell selection - clinical experience. Prog Clin Biol Res 1990;333:403-10.
24. Cottler-Fox M, Cipolone K, Yu M, Berenson R, O'Shaughnessy J, Dunbar C. Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation. Exp Hematol 1995;23:320-2.
25. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991;77:400-9.
26. Tabilio A, Falzetti F, Giannoni C, et al. Stem cell mobilization in normal donors. J Hematother 1997;6:227-34.
27. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997;89:4226-35.
28. Gyapay G, Morissette J, Vignal A, et al. The 1993-94 Généthon human genetic linkage map. Nat Genet 1994;7:Suppl:246-339.
29. Rothberg PG, Gamis AS, Baker D. Use of DNA polymorphisms to monitor engraftment after allogeneic bone marrow transplantation. Clin Lab Med 1997;17:109-18.
30. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237-8. [Erratum, Nature 1989;339:490.]
31. Velardi A, Varese P, Grossi CE, et al. Cytolytic function of clonable T cells after human bone marrow transplantation. Blood 1990;75:1364-9.
32. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
33. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 1995; 16:437-40.
34. Urbano-Ispizua A, Rozman C, Martinez C, et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 1997;11:3967-73.
35. Strober S, Palathumpat V, Schwadron R, Ertel-Wulff B. Cloned natural suppressor cells prevent lethal graft-vs-host disease. J Immunol 1987; 138:699-703.
36. Lapidot T, Faktorowich Y, Lubin I, Reisner Y. Enhancement of T-cell-depleted bone marrow allografts in the absence of graft-versus-host disease is mediated by CD8+ CD4-and not by CD8-CD4+ thymocytes. Blood 1992;80:2406-11.
37. Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84:2436-46.
38. Thomas JM, Verbanac KM, Smith JP, et al. The facilitating effect of one-DR antigen sharing in renal allograft tolerance induced by donor bone marrow in rhesus monkeys. Transplantation 1995;59:245-55.
39. Rachamin N, Gan J, Segall H, et al. Tolerance induction by "mega-dose" hematopoietic transplants: donor-type CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998;65:1386-93.
40. - stem cells can tolerize fully allogeneic host T-cells remaining after sublethal TBI. Blood 1997;90:Suppl 1:563a. abstract.
41. Uchida N, Tsukamoto A, He D, Friera AM, Scollay R, Weissman IL. High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. J Clin Invest 1998;101:961-6.
42. Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 1990;336:850-4.
43. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990;76:1867-71.
44. Woods WG, Ramsay NK, Weisdorf DJ, et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 1990;6:9-16.
45. Petersen FB, Bearman SI. Preparative regimens and their toxicity. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Boston: Blackwell Scientific, 1994:79-95.
46. Schmidt J, Fleissner S, Heimann-Weitschat I, et al. Effect of cortico-steroids, cyclosporin A, and methotrexate on cytokine release from monocytes and T-cell subsets. Immunopharmacology 1994;27:173-9.
47. Lamparelli T, Van Lint MT, Gualandi F, et al. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated or sibling donors: single center experience. Bone Marrow Transplant 1997;20:1057-62.
48. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-30.
49. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-14.
50. Velardi A, Albi N, Ruggeri L, et al. Anti-leukemia T cell-mediated immunity in recipients of mismatched stem cell transplants. Blood 1996;88: Suppl 1:267a. abstract.
51. O'Reilly RJ, Lacerda JF, Lucas KG, Rosenfield NS, Small TN, Papadopoulos EB. Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. Important Adv Oncol 1996;149-66.
52. Ciccone E, Grossi CE, Velardi A. Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T cells. Immunol Today 1996;17:450-3.
53. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996;18:377-82.